FIRST试验最终分析:不适合移植新诊断多发性骨髓瘤一线治疗的生存结局
FIRST试验最终分析纳入不适合移植的新诊断多发性骨髓瘤患者,随机接受Rd持续治疗、Rd18或MPT方案。中位随访67个月时,Rd持续治疗较MPT显著延长无进展生存期(HR 0.69)和总生存期(中位59.1 vs 49.1个月;HR 0.78),支持Rd持续治疗作为标准治疗。
要点
- Rd持续治疗较MPT显著延长PFS(HR 0.69;95%CI 0.59-0.79;P<.00001)。
- Rd持续治疗中位OS较MPT延长10个月(59.1 vs 49.1个月;HR 0.78;P=.0023)。
- 达到完全或非常好的部分缓解者中,Rd持续较Rd18至下次治疗时间延长约30个月(69.5 vs 39.9个月)。
核心结论
- Rd持续治疗较MPT显著改善生存结局,支持Rd持续治疗作为不适合移植新诊断多发性骨髓瘤患者的标准治疗。
研究设计与样本
- 3期FIRST试验最终分析,患者随机接受Rd持续治疗(n=535)、Rd18(n=541)或MPT(n=547)。
- 主要终点为无进展生存期(主要比较:Rd持续 vs MPT);总生存期为关键次要终点,最终分析预设随访≥60个月。
- 中位随访67个月。
主要发现
- Rd持续较MPT显著延长PFS(HR 0.69;95%CI 0.59-0.79;P<.00001),与Rd18相比PFS也相似延长。
- Rd持续中位OS较MPT延长10个月(59.1 vs 49.1个月;HR 0.78;95%CI 0.67-0.92;P=.0023),Rd18中位OS为62.3个月。
- 达到完全或非常好的部分缓解的患者中,Rd持续较Rd18中位至下次治疗时间延长约30个月(69.5 vs 39.9个月)。
- 接受二线治疗的患者中超过半数接受以硼替佐米为基础的治疗;Rd持续和Rd18后接受硼替佐米者的二线结局较MPT后接受者改善。
- 未观察到新的安全性问题,包括第二恶性肿瘤风险。
临床怎么用
- 作者结论认为Rd持续治疗较MPT显著改善生存结局,支持Rd持续作为不适合移植新诊断多发性骨髓瘤患者的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final analysis prespecified ≥60 months' follow-up). Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 547). At a median follow-up of 67 months, PFS was significantly longer with Rd continuous vs MPT (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.59-0.79; P < .00001) and was similarly extended vs Rd18. Median OS was 10 months longer with Rd continuous vs MPT (59.1 vs 49.1 months; HR, 0.78; 95% CI, 0.67-0.92; P = .0023), and similar with Rd18 (62.3 months). In patients achieving complete or very good partial responses, Rd continuous had an ≈30-month longer median time to next treatment vs Rd18 (69.5 vs 39.9 months). Over half of all patients who received second-line treatment were given a bortezomib-based therapy. Second-line outcomes were improved in patients receiving bortezomib after Rd continuous and Rd18 vs after MPT. No new safety concerns, including risk for secondary malignancies, were observed. Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible NDMM. This trial was registered at www.clinicaltrials.gov as #NCT00689936 and EudraCT as 2007-004823-39.
引用
- Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2017. PMID: 29150421. doi:10.1182/blood-2017-07-795047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。